MALACHITE INNOVATIONS AND ITS SUBSIDIARY GRAPHIUM BIOSCIENCES RELEASE NEW INVESTOR PRESENTATIONS AND ANNOUNCE UPCOMING FUNDRAISING EFFORTS
MALACHITE INNOVATIONS AND ITS SUBSIDIARY GRAPHIUM BIOSCIENCES RELEASE NEW INVESTOR PRESENTATIONS AND ANNOUNCE UPCOMING FUNDRAISING EFFORTS
CLEVELAND, OHIO, June 01, 2023 (GLOBE NEWSWIRE) -- MALACHITE INNOVATIONS, INC. (OTC Mkts: MLCT) ("Malachite"), a public company focused on improving the health and wellness of people and the planet, today released new investor presentations for Malachite and its wholly-owned subsidiary, Graphium Biosciences ("Graphium"), and announced upcoming fundraising efforts to further advance its mission-driven strategy.
俄亥俄州克利夫蘭，2023年6月1日(環球通訊社)孔雀石創新公司場外交易市場代碼：MLCT)(以下簡稱“孔雀石”)是一家專注於改善人類和地球健康和福祉的上市公司，該公司今天發佈了孔雀石及其全資子公司石墨生物科學公司(“石墨”)的新投資者介紹，並宣佈即將進行的籌資活動，以進一步推進其使命驅動的戰略。
The Malachite Investor Presentation and Graphium Investor Presentation are available for review and download on the Investors section of Malachite's website at
孔雀石投資者演示文稿和石墨投資者演示文稿可在孔雀石公司網站的投資者部分查閱和下載，網址為：
About Malachite Innovations, Inc.
關於孔雀石創新公司
Headquartered in Cleveland, Ohio, Malachite Innovations, Inc. is a public holding company dedicated to improving the health and wellness of people and the planet through a novel and innovative approach to impact investing. Malachite owns and operates a balanced portfolio of operating businesses focused on developing long-term solutions to environmental, social and health challenges, with a particular focus on economically disadvantaged communities. Malachite takes an opportunistic approach to impact investing by leveraging its competitive advantages and looking at solving old problems in new ways. Malachite seeks to thoughtfully allocate its capital into ventures that are expected to make a positive impact on the people-planet ecosystem and generate strong investment returns for its shareholders.
馬拉契特創新公司總部設在俄亥俄州克利夫蘭，是一家公共控股公司，致力於通過一種新穎和創新的影響投資方法來改善人們和地球的健康和福祉。孔雀石擁有並運營著一個平衡的經營業務組合，專注於開發應對環境、社會和健康挑戰的長期解決方案，特別關注經濟困難的社區。孔雀石採取機會主義的方式進行影響力投資，利用其競爭優勢，並以新的方式解決舊問題。孔雀石尋求深思熟慮地將其資本分配到有望對人類-星球生態系統產生積極影響並為其股東帶來強勁投資回報的企業。
About Graphium Biosciences, Inc.
關於石墨粉生物科學公司
Graphium Biosciences, Inc., a wholly-owned subsidiary of Malachite Innovations, is developing a novel pharmaceutical grade cannabinoid drug poised to disrupt the $20 billion inflammatory bowel disease market. Graphium has invented a proprietary patent-pending glycosylation technology that attaches glucose to cannabinoids, thereby creating a glycosylated cannabinoid that is anticipated to unlock the rebalancing effects of the endocannabinoid system to reduce gastrointestinal inflammation but without any psychoactive side effects. Graphium has developed over 250 glycosylated cannabinoids and endocannabinoids covered by patent filings. Graphium's leading drug candidate (VBX-100), a glycosylated-THC molecule, has been awarded an Orphan Drug Designation by the FDA for pediatric ulcerative colitis. Graphium has developed a drug development plan that advances VBX-100 through its remaining animal studies and Phase I and II clinical studies over a three-year period once sufficient funding is obtained.
孔雀創新公司的全資子公司石墨生物科學公司正在開發一種新的藥用級大麻類藥物，有望擾亂價值200億美元的炎症性腸病市場。Graphium發明了一種正在申請專利的糖基化技術，將葡萄糖連接到大麻素上，從而創造出一種糖基化大麻素，預計將解鎖內源性大麻素系統的再平衡效應，以減少胃腸道炎症，而不會產生任何精神活性副作用。Graphium已經開發了250多種糖基化大麻素和內源性大麻素，這些都是專利申請所涵蓋的。Graphium的主要候選藥物(VBX-100)是一種糖基化的THC分子，已被FDA授予治療兒童潰瘍性結腸炎的孤兒藥物稱號。Graphium已經制定了一項藥物開發計劃，一旦獲得足夠的資金，該計劃將在三年內通過剩餘的動物研究以及第一和第二階段臨床研究推進VBX-100。
Notice Regarding Forward-Looking Statements
關於前瞻性陳述的通知
This press release contains "forward-statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Although we believe that these statements are based on reasonable assumptions, they are subject to numerous factors that could cause actual outcomes and results to be materially different from those indicated in such statements. Such factors include, among others, the (VBX-100) inherent uncertainties associated with new projects and development stage companies, timing of clinical trials and product development, business strategy and new lines of business. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
本新聞稿包含修訂後的1933年證券法第27(A)節和修訂後的1934年證券交易法第21(E)節中定義的“前瞻性陳述”。本新聞稿中非純粹歷史性的陳述為前瞻性陳述，包括有關對未來的信念、計劃、期望或意圖的任何陳述。儘管我們認為這些陳述是基於合理的假設，但它們受到許多因素的影響，這些因素可能導致實際結果和結果與此類陳述中顯示的結果大不相同。這些因素包括(VBX-100)與新專案和開發階段公司相關的固有不確定性、臨床試驗和產品開發的時間安排、業務戰略和新的業務線。這些前瞻性陳述是截至本新聞稿發佈之日作出的，我們沒有義務更新前瞻性陳述，也沒有義務更新實際結果可能與前瞻性陳述中預測的結果不同的原因。儘管我們相信本新聞稿中包含的任何信念、計劃、預期和意圖都是合理的，但不能保證任何此類信念、計劃、預期或意圖將被證明是準確的。投資者應參考此處列出的所有資訊，也應參考我們最近財年的Form 10-K年度報告、Form 10-Q季度報告和其他不定期提交給美國證券交易委員會的報告中概述的風險因素披露。
Malachite Innovations, Inc.
Investor Relations
P: +1 (216) 304-6556
E: ir@malachiteinnovations.com
W:
孔雀石創新公司
投資者關係
電話：+1(216)304-6556
電子郵箱：ir@marachiteInnovations.com
W：
譯文內容由第三人軟體翻譯。